A method of detecting a target in a sample, comprising: contacting the sample with a first PNA conjugate, the first PNA conjugate having the structure of Formula (IIB): wherein 'Specific binding entity' is selected from the group consisting of an antibody, an antibody fragment, a drug/antibody complex, and a nucleic acid; 'Linker' is a branched or unbranched, linear or cyclic, substituted or unsubstituted, saturated or unsaturated, group having between 2 and 80 carbon atoms, and optionally having one or more heteroatoms selected from O, N, or S, wherein the 'Linker' includes a cleavable moiety; 'PNA' is a PNA sequence having at least one nucleotide including a substitution at a gamma carbon position; X is selected from the group consisting of biotin, an enzyme, a chromogen, a fluorophore, a hapten, and a mass spectrometry tag; Y is a branched or unbranched, linear or cyclic, substituted or unsubstituted, saturated or unsaturated group having between 1 and 12 carbon atoms and optionally having one or more O, N, or S heteroatoms; m is 0; z is 0; and n is an integer ranging from 1 to 12; and contacting the sample with a reagent to cleave the cleavable moiety on the 'Linker,' and quantifying an amount of the cleaved 'PNA' sequence. contacting the sample with a first PNA conjugate, the first PNA conjugate having the structure of Formula (IIB): wherein 'Specific binding entity' is selected from the group consisting of an antibody, an antibody fragment, a drug/antibody complex, and a nucleic acid; 'Linker' is a branched or unbranched, linear or cyclic, substituted or unsubstituted, saturated or unsaturated, group having between 2 and 80 carbon atoms, and optionally having one or more heteroatoms selected from O, N, or S, wherein the 'Linker' includes a cleavable moiety; 'PNA' is a PNA sequence having at least one nucleotide including a substitution at a gamma carbon position; X is selected from the group consisting of biotin, an enzyme, a chromogen, a fluorophore, a hapten, and a mass spectrometry tag; Y is a branched or unbranched, linear or cyclic, substituted or unsubstituted, saturated or unsaturated group having between 1 and 12 carbon atoms and optionally having one or more O, N, or S heteroatoms; m is 0; z is 0; and n is an integer ranging from 1 to 12; and 'Specific binding entity' is selected from the group consisting of an antibody, an antibody fragment, a drug/antibody complex, and a nucleic acid; 'Linker' is a branched or unbranched, linear or cyclic, substituted or unsubstituted, saturated or unsaturated, group having between 2 and 80 carbon atoms, and optionally having one or more heteroatoms selected from O, N, or S, wherein the 'Linker' includes a cleavable moiety; 'PNA' is a PNA sequence having at least one nucleotide including a substitution at a gamma carbon position; X is selected from the group consisting of biotin, an enzyme, a chromogen, a fluorophore, a hapten, and a mass spectrometry tag; Y is a branched or unbranched, linear or cyclic, substituted or unsubstituted, saturated or unsaturated group having between 1 and 12 carbon atoms and optionally having one or more O, N, or S heteroatoms; m is 0; z is 0; and n is an integer ranging from 1 to 12; and contacting the sample with a reagent to cleave the cleavable moiety on the 'Linker,' and quantifying an amount of the cleaved 'PNA' sequence. <EOS>